Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Saunders

Showing results (41-50 of 89) with videos related to

Pageof 9
Sort By:
The Medical Journal of Australia|September 16, 2014
Markers of hepatitis B infection and immunity in patients attending Aboriginal community controlled health servicesMary E Harrod, Sophia Couzos, Dea Delaney-Thiele, et al.
BMC Health Services Research|July 2, 2014
Chlamydia among Australian Aboriginal and/or Torres Strait Islander people attending sexual health services, general practices and Aboriginal community controlled health servicesJames Ward, Jane Goller, Hammad Ali, et al.
Cancer Research|February 7, 2002
Interleukin-12 inhibits angiogenesis and growth of transplanted but not in situ mouse mammary tumor virus-induced mammary carcinomasJames C Lee, David C Kim, Michael S Gee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2005
Noninvasive monitoring of murine tumor blood flow during and after photodynamic therapy provides early assessment of therapeutic efficacyGuoqiang Yu, Turgut Durduran, Chao Zhou, et al.
Current Treatment Options in Oncology|September 26, 2024
Clinical Trial Data Review of the Combination FTD/TPI + Bevacizumab in the Treatment Landscape of Unresectable Metastatic Colorectal CancerThierry André, Eric Van Cutsem, Julien Taieb, et al.
Sexual Health|June 23, 2017
Gonorrhoea testing and positivity in non-remote Aboriginal Community Controlled Health ServicesMary Ellen Harrod, Sophia Couzos, James Ward, et al.
Cancer Chemotherapy and Pharmacology|October 19, 2017
Randomized study of etirinotecan pegol versus irinotecan as second-line treatment for metastatic colorectal cancerHeinz-Josef Lenz, Philip Philip, Mark Saunders, et al.
Pharmacogenomics|May 20, 2009
UGT1A1*28 genotype predicts gastrointestinal toxicity in patients treated with intermediate-dose irinotecanRoberta Ferraldeschi, Laura J Minchell, Stephen A Roberts, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 26, 2011
Preoperative chemoradiotherapy using concurrent capecitabine and irinotecan in magnetic resonance imaging-defined locally advanced rectal cancer: impact on long-term clinical outcomesSimon Gollins, Arthur Sun Myint, Brian Haylock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2006
Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trialRichard Harrop, Noel Connolly, Irina Redchenko, et al.
Pageof 9

Showing results (41-50 of 89) with videos related to

Sort By:
Pageof 9
The Medical Journal of Australia|September 16, 2014
Markers of hepatitis B infection and immunity in patients attending Aboriginal community controlled health servicesMary E Harrod, Sophia Couzos, Dea Delaney-Thiele, et al.
BMC Health Services Research|July 2, 2014
Chlamydia among Australian Aboriginal and/or Torres Strait Islander people attending sexual health services, general practices and Aboriginal community controlled health servicesJames Ward, Jane Goller, Hammad Ali, et al.
Cancer Research|February 7, 2002
Interleukin-12 inhibits angiogenesis and growth of transplanted but not in situ mouse mammary tumor virus-induced mammary carcinomasJames C Lee, David C Kim, Michael S Gee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2005
Noninvasive monitoring of murine tumor blood flow during and after photodynamic therapy provides early assessment of therapeutic efficacyGuoqiang Yu, Turgut Durduran, Chao Zhou, et al.
Current Treatment Options in Oncology|September 26, 2024
Clinical Trial Data Review of the Combination FTD/TPI + Bevacizumab in the Treatment Landscape of Unresectable Metastatic Colorectal CancerThierry André, Eric Van Cutsem, Julien Taieb, et al.
Sexual Health|June 23, 2017
Gonorrhoea testing and positivity in non-remote Aboriginal Community Controlled Health ServicesMary Ellen Harrod, Sophia Couzos, James Ward, et al.
Cancer Chemotherapy and Pharmacology|October 19, 2017
Randomized study of etirinotecan pegol versus irinotecan as second-line treatment for metastatic colorectal cancerHeinz-Josef Lenz, Philip Philip, Mark Saunders, et al.
Pharmacogenomics|May 20, 2009
UGT1A1*28 genotype predicts gastrointestinal toxicity in patients treated with intermediate-dose irinotecanRoberta Ferraldeschi, Laura J Minchell, Stephen A Roberts, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 26, 2011
Preoperative chemoradiotherapy using concurrent capecitabine and irinotecan in magnetic resonance imaging-defined locally advanced rectal cancer: impact on long-term clinical outcomesSimon Gollins, Arthur Sun Myint, Brian Haylock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2006
Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trialRichard Harrop, Noel Connolly, Irina Redchenko, et al.
Pageof 9